The potential of GDNF as a treatment for Parkinson's disease

Author： Hurelbrink C.B.   Barker R.A.  

Publisher： Elsevier

ISSN： 0014-4886

Source： Experimental Neurology, Vol.185, Iss.1, 2004-01, pp. : 1-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

GDNF treatment in Parkinson’s disease: time for controlled clinical trials?

By Brundin Patrik  

Brain, Vol. 125, Iss. 10, 2002-10 ,pp. : 2149-2151

Oxford University Press

Access to resources Recommend Favorite

The Potential Neuroprotection Mechanism of GDNF in the 6-OHDA-Induced Cellular Models of Parkinson’s Disease

By Li Feng   Wang Meng   Zhu Shuan   Li Li   Xiong Ye   Gao Dian-Shuai  

Cellular and Molecular Neurobiology, Vol. 33, Iss. 7, 2013-10 ,pp. : 907-919

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacological Activities of Glial Cell Line-Derived Neurotrophic Factor (GDNF): Preclinical Development and Application to the Treatment of Parkinson's Disease

By Lapchak P.A.   Gash D.M.   Collins F.   Hilt D.   Miller P.J.   Araujo D.M.  

Experimental Neurology, Vol. 145, Iss. 2, 1997-06 ,pp. : 309-321

Elsevier

Access to resources Recommend Favorite

Studies on Neuroprotective and Regenerative Effects of GDNF in a Partial Lesion Model of Parkinson's Disease

By Bjorklund A.   Rosenblad C.   Winkler C.   Kirik D.  

Neurobiology of Disease, Vol. 4, Iss. 3, 1997-03 ,pp. : 186-200

Academic Press

Access to resources Recommend Favorite

Adenosine A 2A antagonists: potential preventive and palliative treatment for Parkinson's disease

By Morelli M.  

Experimental Neurology, Vol. 184, Iss. 1, 2003-11 ,pp. : 20-23

Elsevier

Access to resources Recommend Favorite